Kobe University Hospital

Running trials

• Recruiting

  A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer

  NCT07832292· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT07744126· Phase 2· AbbVie· Source

• Recruiting

  A Study of LY3971297 in Participants With Heart Failure

  NCT07547540· Phase 1· Eli Lilly and Company· Source

• Recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

  NCT07365241· Phase 3· AbbVie· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

  NCT07589595· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

  NCT07419295· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of E6742 in Participants With Systemic Lupus Erythematosus

  NCT07515014· Phase 2· Eisai Co., Ltd.· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

  NCT07332481· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  Pancreatic Cancer Screening Using the Enzeavour Assay in Japan

  NCT07605819· Cosomil, Inc.· Source

• Recruiting

  A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

  NCT07128199· Phase 3· Taiho Oncology, Inc.· Source

• Recruiting

  A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07225946· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  NCT07213674· Phase 3· Amgen· Source

• Recruiting

  Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis

  NCT07136116· AbbVie· Source

• Recruiting

  A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy

  NCT07356778· Phase 4· Kazuya Hosokawa· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Pfizer· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

  NCT07071519· Phase 3· AbbVie· Source

• Active, not recruiting

  Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease

  NCT06987695· Phase 3· Amgen· Source

• Active, not recruiting

  A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

  NCT06806852· Phase 1· Boehringer Ingelheim· Source

• Recruiting

  A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

  NCT06925737· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Phase 2b Open-Label Repeat Kidney Biopsy Study

  NCT06740526· Phase 2· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

  NCT06663332· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

  NCT06653153· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

  NCT06629779· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

  NCT06551324· Phase 3· Pfizer· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

  NCT06510374· Phase 3· Ferring Pharmaceuticals· Source

• Active, not recruiting

  Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06564142· Phase 3· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Source

• Recruiting

  A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  NCT06452277· Phase 3· Bayer· Source

• Recruiting

  A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

  NCT06226883· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source

• Active, not recruiting

  A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

  NCT06456580· Phase 3· Vor Biopharma· Source

• Recruiting

  A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

  NCT05923073· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

  NCT05509777· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06260163· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

  NCT06116916· Phase 2· Kyowa Kirin Co., Ltd.· Source

• Recruiting

  Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

  NCT06136624· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

  NCT06136650· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

  NCT06113445· Phase 3· Incyte Corporation· Source

• Recruiting

  A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors

  NCT06248411· Phase 1· Kyowa Kirin Co., Ltd.· Source

• Enrolling by invitation

  A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

  NCT05967351· Phase 3· Sarepta Therapeutics, Inc.· Source

• Active, not recruiting

  Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

  NCT05911295· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

  NCT05648500· Phase 3· Viatris Innovation GmbH· Source

• Active, not recruiting

  A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

  NCT05476926· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05242484· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)

  NCT05814159· Phase 3· Swedish Orphan Biovitrum· Source

Showing 50 of 67.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer8 recruiting
• Crohn's disease6 recruiting
• Lung cancer4 recruiting
• Ulcerative colitis4 recruiting
• Head and neck cancer3 recruiting
• Lupus (SLE)3 recruiting
• Bladder cancer2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Heart failure2 recruiting
• Pancreatic cancer2 recruiting
• Alzheimer disease1 recruiting
• Amyloidosis1 recruiting
• Colorectal cancer1 recruiting
• Congenital heart disease1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Gastric and oesophageal cancer1 recruiting
• High blood pressure1 recruiting
• Lewy body dementia1 recruiting
• Liver and biliary tract cancer1 recruiting
• Liver cirrhosis1 recruiting
• Ovarian cancer1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Recruiting

  A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

  NCT06321302· Phase 2· Boehringer Ingelheim· Source

• Completed

  JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study

  NCT06412848· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source

• Completed

  A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

  NCT06323356· Phase 3· Takeda· Source

• Completed

  Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

  NCT06116890· Phase 2· Kyowa Kirin Co., Ltd.· Source

• Completed

  A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease

  NCT06176365· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

  NCT06066515· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

  NCT06137742· Phase 1/2· Pfizer· Source

• Completed

  A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)

  NCT05818137· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  An Observational Study to Assess Change in Disease Activity and Adverse Events of Rinvoq in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Japan

  NCT05791526· AbbVie· Source

• Completed

  A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

  NCT05651711· Phase 3· Amgen· Source

• Completed

  POLARx™ Cardiac Cryoablation System Post Market Clinical Study (POLAR SMART)

  NCT05282823· Boston Scientific Corporation· Source

• Completed

  Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)

  NCT05679570· Phase 2· International University of Health and Welfare· Source

• Completed

  Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)

  NCT05174065· Phase 3· Amgen· Source

• Completed

  A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

  NCT05096221· Phase 3· Sarepta Therapeutics, Inc.· Source

• Terminated

  A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

  NCT05085366· Phase 3· ModernaTX, Inc.· Source

• Completed

  A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

  NCT05047263· Phase 3· Bayer· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

  NCT04704154· Phase 2· Bayer· Source

• Completed

  The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

  NCT04338399· Phase 3· Adlai Nortye Biopharma Co., Ltd.· Source

• Completed

  Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

  NCT04472598· Phase 3· AbbVie· Source

• Completed

  Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

  NCT04423718· Phase 3· Bayer· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®

  NCT04469855· Novo Nordisk A/S· Source

• Terminated

  A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

  NCT04271475· Phase 3· Actelion· Source

• Completed

  Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ Tablets

  NCT04340115· AbbVie· Source

• Completed

  Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

  NCT05694819· Phase 2· National Cancer Center Hospital East· Source

• Completed

  Registry of Asthma Patients Initiating DUPIXENT®

  NCT04287621· Regeneron Pharmaceuticals· Source

• Completed

  A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

  NCT04169373· Phase 3· AbbVie· Source

• Completed

  Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

  NCT04036435· Phase 3· Bristol-Myers Squibb· Source

• Completed

  Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

  NCT03904693· Phase 3· Actelion· Source

• Completed

  A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

  NCT04034095· Janssen Pharmaceutical K.K.· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Boehringer Ingelheim· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

  NCT03221426· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

  NCT03025308· Phase 3· Alfasigma S.p.A.· Source

• Completed

  A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )

  NCT03047395· Phase 3· AbbVie· Source

• Completed

  Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease

  NCT02906488· AbbVie· Source

• Completed

  Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III

  NCT02761070· Phase 3· Kyorin University· Source

• Completed

  A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

  NCT02038777· Phase 1· Pfizer· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Head and neck cancer11 works · 7 trials
• Cytomegalovirus infection9 works · 1 trial